Japan· JP-2325003B1022
ファモチジン
A famotidine product containing ファモチジン, registered in Japan by LTLファーマ, on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Famotidine is registered in 15 of 19 countries.
Countries holding a registration under ATC A02BA03 (famotidine), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 8 of them publish a price we can compare per daily dose
Famotidine · ATC A02BA03
15 / 19 countries
- Canada
- Czechiaprice
- Finlandprice
- Franceprice
- Germany
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of famotidine costs, country by country.
Normalised to the WHO defined daily dose (40 mg), the median price runs from $0.26 in Spain to $0.76 in Italy — a ×3.0 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Famotidine · price per daily dose (40 mg)
USD · FX 28 Sept 2026
- IT Italy$0.76
- FR France$0.59
- ES Spain$0.26
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- ファモチジン
- Manufacturer
- LTLファーマ
- Country
- Japan (JP)
- ATC code
- A02BA03
- ATC class
- Famotidine
- Defined daily dose
- 40 mg, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
778 interactions on record for famotidine.
Graded by severity as the source publishes them — 14 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Famotidine · interactions on record
778 records
- 14 severe
- 277 moderate
- 52 minor
- 434 info
Most severe, free to view
- AtazanavirJ05AE08severe
- RilpivirineJ05AG05severe
- DasatinibL01EA02severe
- NeratinibL01EH02severe
1 more interaction with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under A02BA03
Famotidine, as other registers publish it.
- United Statesacid controllerCVS Pharmacy
- United Statesacid controllerSafeway
- United Statesacid controllerCVS Pharmacy
- United Statesacid controllerH E B
- United Statesacid controllerWalgreen Company
- United StatesAcid ControllerWalgreen Company
- United StatesAcid ControllerH E B
- United StatesAcid ControllerH E B
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c749a592-77b9-4497-9b2c-87f61f070d32 GET /v1/drugs/c749a592-77b9-4497-9b2c-87f61f070d32?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "10%1g",
"marks": "局",
"source": "mhlw",
"remarks": null,
"yj_code": "2325003B1022",
"category": "内用薬",
"price_yen": 37.3,
"generic_name": "ファモチジン",
"product_name_jp": null,
"therapeutic_class": "2325",
"transitional_expiry": null
}See everything about famotidine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.